Assessing complications from retroperitoneal lymph node dissection for testicular cancer in North America

Authors

  • Mithun Kailavasan Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.
  • Jose de Jesus Cendejas-Gomez Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.
  • Melissa J. Huynh Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.
  • Brant A. Inman Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.
  • Nicholas Power Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.

DOI:

https://doi.org/10.5489/cuaj.9042

Keywords:

Retroperitoneal Lymph Node Dissection, Surgical Quality, Complications, Testicular Cancer

Abstract

INTRODUCTION: Retroperitoneal lymph node dissection (RPLND) is a procedure of significant therapeutic and diagnostic value in the management of testicular cancer. This study aimed to conduct a contemporary review of surgical outcomes following RPLND procedures performed in North America over the last decade.

METHODS: We queried the National Surgical Quality Improvement Program (NSQIP) database from 2012-2022 (n=9 857 040) to identify patients who underwent RPLND and were diagnosed with testicular cancer. The primary outcome was 30-day morbidity. Secondary outcomes included time-to-complication analysis, rate of additional organ resection, hospital length of stay (LOS), and readmission rates. Binomial logistic regression and a generalized linear model were used to identify risk factors associated with 30-day morbidity and LOS.

RESULTS: A total of 513 RPLND procedures met the inclusion criteria. The median age was 30 years (interquartile range [IQR] 24-36.50) with a body mass index of 27.9 kg/m2 (IQR 24.5– 32.0). There were no deaths within 30 days. The overall 30-day morbidity rate was 17% (n=86). Bleeding/transfusion postoperatively (12%), return to the operating room (3%), and superficial surgical-site infection (2%) were the three most common complications. Factors associated with increased 30-day morbidity included: history of smoking (odds ratio [OR] 2.5, 95% confidence interval [CI] 1.35–4.68) and concurrent vascular repair/reconstruction (OR 4.1, 95% CI 1.12–15.46). The median LOS was four days (IQR 3–6) and the 30-day readmission rate was 7.0%.

CONCLUSIONS: This study underscores that approximately one in six patients experience complications following RPLND in North America. Identifying the timing of and risk factors for these complications can improve physician-patient communication and overall care.

Downloads

Download data is not yet available.

Downloads

Published

2025-02-24

How to Cite

Kailavasan, M., Cendejas-Gomez, J. de J., Huynh, M. J., Inman, B. A., & Power, N. (2025). Assessing complications from retroperitoneal lymph node dissection for testicular cancer in North America. Canadian Urological Association Journal, 19(6), 167–72. https://doi.org/10.5489/cuaj.9042

Issue

Vol. 19 No. 6 (2025): CUAJ June

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.